What is the Fennec Pharmaceuticals Inc. stock price forecast?

Fennec Pharmaceuticals Inc. is currently trading at $9.23. View real-time AI analysis on Alpha Lenz.

What is Fennec Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Fennec Pharmaceuticals Inc. on Alpha Lenz.

What is Fennec Pharmaceuticals Inc.'s P/E ratio?

Fennec Pharmaceuticals Inc.'s P/E ratio is -27.1.

Fennec Pharmaceuticals Inc.

NASDAQ · FENC

$9.23+2.46(+36.34%)Pre-market

Ask about Fennec Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Fennec Pharmaceuticals Inc. trades at a P/E of -27.1 (undervalued) with modest ROE of -65.8%. 3Y revenue CAGR of 207.5% highlights clear growth momentum.”

Ask for details →

Company Overview

Fennec Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer. The company's flagship product candidate, Pedmark, is designed to reduce ototoxicity, or hearing loss, in pediatric cancer patients undergoing chemotherapy. With a commitment to addressing unmet medical needs, Fennec Pharmaceuticals operates at the intersection of oncology and supportive cancer care. By focusing on niche markets, particularly in pediatric cancer, the company positions itself within a critical area of the pharmaceutical industry. Based in the United States, Fennec Pharmaceuticals is actively involved in the advancement of its clinical trials, seeking to bring its novel solutions to the forefront of cancer treatment. The company plays a significant role in enhancing the quality of life for young cancer patients and underscores the ongoing innovation in pharmaceutical care and therapeutic development.

CEOMr. Jeffrey S. Hackman

Websitehttps://fennecpharma.com

SectorHealthcare

IndustryBiotechnology

Employees32

Company Statistics

FY 2025

Profile

$263.77MMarket Cap

$44.64MRevenue

0.00Shares Out

32Employees

Margins

91.57%Gross

-12.22%EBITDA

-14.22%Operating

-21.58%Pre-Tax

-21.82%Net

Valuation

-27.08P/E

7.44P/B

5.91EV/Sales

-41.60EV/EBITDA

-21.15P/FCF

Growth (CAGR)

207.52%Rev 3Yr

204.69%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-16.87%ROA

-65.82%ROE

-13.08%ROIC

Financial Health

$36.79MCash & Cash Equivalents

$-1.71MNet Debt

98.89%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Fennec Pharmaceuticals Inc. trades at a P/E of -27.1 (undervalued) with modest ROE of -65.8%. 3Y revenue CAGR of 207.5% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Fennec Pharmaceuticals Inc. (ticker: FENC) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 32 employees. Market cap is $264M.

The current price is $9.23 with a P/E ratio of -27.08x and P/B of 7.44x.

ROE is -65.82% and operating margin is -14.22%. Annual revenue is $45M.